| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/15/2009 | US20090018134 Compounds - 945 |
| 01/15/2009 | US20090018133 Novel Adamantane Derivatives |
| 01/15/2009 | US20090018132 Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| 01/15/2009 | US20090018131 Quinazoline derivatives as p13 kinase inhibitors |
| 01/15/2009 | US20090018130 Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid |
| 01/15/2009 | US20090018129 compounds that interfere with tyrosine kinase signalling such as 1-{3-Amino-1-methyl-4-[4-(3-phenyl-ureido)-phenyl]-1H-pyrazolo[3,4-b]pyridin-6-yl}-cyclopropanecarboxylic acid ethyl ester, used for the treatment of diseases of dysregulated vascular growth such as retinopathy |
| 01/15/2009 | US20090018128 Compounds |
| 01/15/2009 | US20090018127 (6aR,9R)-9-(Pyrrolidine-1-carbonyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7-carboxylic acid phenylamide; preventing or treating disorders or diseases mediated by chemokine receptors; antiinflammatory agents treating inflammatory or autoimmune diseases; chemical preparation |
| 01/15/2009 | US20090018126 pyrimidine- or pyridinecarboxylic acid derivatives which are substituted in the 2- or 4-position by an optionally substituted 4-(3-oxomorpholin-4-yl)aniline radical, such as 6-methyl-2-[4-(3-oxomorpholin-4-yl)phenylamino]nicotinic acid, suitable for the treatment of viral diseases, such as hepatitis C |
| 01/15/2009 | US20090018125 Pharmaceutical Composition and Its Use |
| 01/15/2009 | US20090018124 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same |
| 01/15/2009 | US20090018123 Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation |
| 01/15/2009 | US20090018122 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines |
| 01/15/2009 | US20090018121 Preventive and/or therapeutic agent for rheumatoid arthritis |
| 01/15/2009 | US20090018120 Amidine derivatives and their applications as a medicament |
| 01/15/2009 | US20090018119 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 01/15/2009 | US20090018118 Heterocyclic compounds |
| 01/15/2009 | US20090018117 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof |
| 01/15/2009 | US20090018116 Therapeutic Compounds |
| 01/15/2009 | US20090018115 Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| 01/15/2009 | US20090018114 Novel compounds as cannabinoid receptor ligands |
| 01/15/2009 | US20090018113 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof |
| 01/15/2009 | US20090018112 Compounds and Uses Thereof |
| 01/15/2009 | US20090018111 Novel Antimicrobial Medicament |
| 01/15/2009 | US20090018110 Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (SAH) |
| 01/15/2009 | US20090018109 Combinations of steroids and methylxanthine compounds |
| 01/15/2009 | US20090018108 Treating skin hyperpigmentation with dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin |
| 01/15/2009 | US20090018107 Novel composition to increase muscle strength |
| 01/15/2009 | US20090018106 Intravenous formulations of pyridoxal 5'- phosphate and method of preparation |
| 01/15/2009 | US20090018105 Means and Methods for the Treatment and Prevention of Allergic Diseases |
| 01/15/2009 | US20090018104 Triarylcarboxylic Acid Derivative |
| 01/15/2009 | US20090018103 Diaminoalkane Aspartic Protease Inhibitors |
| 01/15/2009 | US20090018102 Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith |
| 01/15/2009 | US20090018101 S-adenosyl-l-methionine analogs with extended activated groups for transfer by methyltransferases |
| 01/15/2009 | US20090018100 Materials and methods for treating ocular-related disorders |
| 01/15/2009 | US20090018099 Protein production |
| 01/15/2009 | US20090018098 Targeting the absence: homozygous dna deletions as signposts for cancer therapy |
| 01/15/2009 | US20090018097 Modification of double-stranded ribonucleic acid molecules |
| 01/15/2009 | US20090018096 Methods For Regulating The Growth And/Or Survival Of Tumor Cells And Stem Cells By Modulating The Expression Or Function Of The Transcription Factor ATF5 |
| 01/15/2009 | US20090018095 Antigen, nucleic acid encodes fusion protein; polynucleotides; nucleoside sequences |
| 01/15/2009 | US20090018094 Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
| 01/15/2009 | US20090018093 Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics |
| 01/15/2009 | US20090018092 Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
| 01/15/2009 | US20090018091 Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use |
| 01/15/2009 | US20090018090 Process for preparation of anhydrous azithromycin |
| 01/15/2009 | US20090018089 Crystalline forms of macrolide compounds endowed with antiinflammatory activity |
| 01/15/2009 | US20090018088 Treating cancer with cardiac glycosides |
| 01/15/2009 | US20090018087 Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism |
| 01/15/2009 | US20090018079 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/15/2009 | US20090018071 Epididymis-specific receptor protein |
| 01/15/2009 | US20090018068 G-protein coupled receptors |
| 01/15/2009 | US20090018058 Vitamin D Receptor Modulators |
| 01/15/2009 | US20090018057 OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES |
| 01/15/2009 | US20090018056 Heteroarylcarbamoylbenzene derivatives |
| 01/15/2009 | US20090018055 [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
| 01/15/2009 | US20090018054 Cholesteryl Ester Transfer Protein Inhibitors |
| 01/15/2009 | US20090018052 Treatment of Diabetes and Related Pathologies |
| 01/15/2009 | US20090017559 Methods for diagnosing renal disorders |
| 01/15/2009 | US20090017508 Streptomyces Avermitilis Gene Directing The Ratio of B2:B1 Avermectins |
| 01/15/2009 | US20090017473 Compositions and methods for the diagnosis and treatment of tumor |
| 01/15/2009 | US20090017145 Tri ascorbate formulation |
| 01/15/2009 | US20090017140 Maytenus abenfolia extract and methods of extracting and using such extract |
| 01/15/2009 | US20090017136 Formulation to prevent and treat fibromyalgia, depression and other muscle and nervous system disorders |
| 01/15/2009 | US20090017127 once-daily oral administration relief of muscle spasm associated with painful musculoskeletal conditions over 24 hours; patient compliance, side effect reduction |
| 01/15/2009 | US20090017126 Modified Release Dosage Forms of Skeletal Muscle Relaxants |
| 01/15/2009 | US20090017124 Nucleic Acid Microparticles for Pulmonary Delivery |
| 01/15/2009 | US20090017123 Dermal regeneration enhancer |
| 01/15/2009 | US20090017122 Drug Forms Having Controlled Bioavailability |
| 01/15/2009 | US20090017121 dispersed in a polymerc matrix comprising swellable hydrophilic polyethylene oxide that swells unrestrained dimensionally by imbibing H2O to increase its size to promote gastric retention of the dosage form in a stomach in fed mode, upon contact with H2O gabapentin released by diffusion; bioavailability |
| 01/15/2009 | US20090017117 Pellet formulation for the treatment of the intestinal tract |
| 01/15/2009 | US20090017114 Tranexamic acid formulations with reduced adverse effects |
| 01/15/2009 | US20090017112 Compounds for Inhibiting Beta-Amyloid Production |
| 01/15/2009 | US20090017111 Tolterodine bead |
| 01/15/2009 | US20090017110 Modified release formulations of anti-irritability drugs |
| 01/15/2009 | US20090017109 Method of reducing somnolence in patients treated with tizanidine |
| 01/15/2009 | US20090017107 Novel composition to increase libido |
| 01/15/2009 | US20090017106 Adjuvants on the basis of bisacyloxypropylcystene conjugates and derivatives and their uses in pharmaceutical compositions |
| 01/15/2009 | US20090017104 Compositions containing retinoid and beta-aminoisobutyic acid derivatives |
| 01/15/2009 | US20090017103 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 01/15/2009 | US20090017102 Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion |
| 01/15/2009 | US20090017099 Cholesterol-rich composite food that is rendered substantially non-cholesterolemic using phytosterols |
| 01/15/2009 | US20090017098 Composition and method for the prevention and relief of the symptoms of an incompetent or patulous eustachian tube |
| 01/15/2009 | US20090017097 Hydrogel polymeric compositions and methods |
| 01/15/2009 | US20090017091 Sterile hyaluronic acid polymer compositions and related methods |
| 01/15/2009 | US20090017089 Multiple active agents such as anthelmintics sustained release delivery device |
| 01/15/2009 | US20090017084 skin-friendly formulations comprising permethrin and agonists or antagonists of nicotinic acetylcholine receptors of insects, in particular imidacloprid, for controlling parasitic insects on animals |
| 01/15/2009 | US20090017078 Anhydrous topical formulation for polyphenols |
| 01/15/2009 | US20090017077 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/15/2009 | US20090017076 Treatment for cd5+ b cell lymphoma |
| 01/15/2009 | US20090017075 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 01/15/2009 | US20090017052 Methods of determining lethality of pathogens and malignancies involving replikin peak genes |
| 01/15/2009 | US20090017047 Preparation for the Prevention and Treatment of Stress Conditions as Well as Functional and Organic Disorders of the Nervous System and Metabolic Disorders |
| 01/15/2009 | US20090017044 Antibodies to the Human Prolactin Receptor |
| 01/15/2009 | US20090017039 SP35 Antibodies and uses thereof |
| 01/15/2009 | US20090017038 Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods |
| 01/15/2009 | US20090017036 Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| 01/15/2009 | US20090017025 Combinations Comprising a CDK Inhibitor and a Growth Factor Antibody or Anti-Mitotic |
| 01/15/2009 | US20090017024 Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders |
| 01/15/2009 | US20090017021 Methods and compositions for inducing innate immune responses |
| 01/15/2009 | US20090017019 Methods and compositions for modulating bmp-10 activity |